IMCR
NASDAQ
$34.05
Immunocore Holdings plc (IMCR)
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $63.37 (+86.11%)
Market Cap
$1.76B
Free Cash Flow Yield
-1.74%
Beta (5Y)
0.70
Price Chart
Valuation
Market Cap$1.76B
Forward P/E232.56
P/S4.27
P/B4.33
Profitability
Total Revenue (TTM)$413M
Gross Profit (TTM)$133M
EBITDA-$31M
Profit Margin12.2%
Operating Margin6.8%
EPS-$0.55
Financial Health
Free Cash Flow Yield-1.74%
Growth & Risk
Beta (5Y)0.70
Sharpe Ratio-0.08